Literature DB >> 21371841

Use of magnetic resonance imaging to detect neoplastic meningitis: limited use in leukemia and lymphoma but convincing results in solid tumors.

Sandra Pauls1, Ann-Cathrin Fischer, Hans-Jürgen Brambs, Sebastian Fetscher, Wolfram Höche, Martin Bommer.   

Abstract

BACKGROUND: An early diagnosis of meningitis is important to improve patients' survival. Data about a direct comparison of cerebrospinal fluid cytology (CSF-cytology) and MRI are very limited. Therefore, the aim of this study was to compare these two diagnostic modalities in diagnosing meningitis in patients with hematopoietic and solid malignancies.
METHODS: In 68 patients suspicious for neoplastic meningitis, cytology and MRI (1.5 T) was performed. The meningeal, pial or intraparenchymal hyperintense signal or contrast enhancement was correlated to the final CNS diagnosis and to cytology.
RESULTS: 44 patients (64.7%) had neoplastic meningitis, 21 patients (30.9%) had non-neoplastic meningitis. The sensitivity to diagnose meningeal disease was 49.2% for MRI and 95.4% for cytology (p<0.001). In patients with neoplastic meningitis, sensitivity was 45.5% for MRI and 93.2% for cytology (p<0.001). In patients with infectious meningitis, sensitivity was 57.1% for MRI and 100% for cytology (p=0.0013). In patients with solid tumors, the sensitivity was 84.6% for both diagnostic methods. The sensitivity for MRI was low in patients with leukemia (20.0%) and lymphoma (37.5%). The positive predictive value (PPV) for MRI to differentiate infectious from neoplastic meningitis was high in patients with infectious meningitis (75.0%), in patients with lymphoma (83.3%), and in patients with solid tumors (72.7%). Ppv was low in patients with leukemia (33.3%).
CONCLUSION: Diagnostic value of MRI for diagnosing meningitis is especially limited in patients with hematopoietic malignancies. MRI better detected leptomeningeal involvement caused by solid tumors than by leukemia or lymphoma. The ppv to specify neoplastic meningitis depends on tumor subtype.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21371841     DOI: 10.1016/j.ejrad.2011.02.020

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  18 in total

Review 1.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.

Authors:  Manmeet S Ahluwalia; Kevin Becker; Benjamin P Levy
Journal:  Oncologist       Date:  2018-04-12

Review 2.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Authors:  Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2014-05-27       Impact factor: 12.300

3.  Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Authors:  Francisco-Javier Peñalver; Juan-Manuel Sancho; Adolfo de la Fuente; María-Teresa Olave; Alejandro Martín; Carlos Panizo; Elena Pérez; Antonio Salar; Alberto Orfao
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

Review 4.  Neuro-ophthalmologic complications of neoplastic leptomeningeal disease.

Authors:  Gabriella Szatmáry
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

Review 5.  Diagnosis of acute leukemia in cerebrospinal fluid (CSF-acute leukemia).

Authors:  Erick Crespo-Solis; Xavier López-Karpovitch; Jesús Higuera; Beatriz Vega-Ramos
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 6.  Leptomeningeal metastases: a RANO proposal for response criteria.

Authors:  Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

7.  Leptomeningeal disease following stereotactic radiosurgery for brain metastases from breast cancer.

Authors:  Daniel M Trifiletti; Kara D Romano; Zhiyuan Xu; Kelli A Reardon; Jason Sheehan
Journal:  J Neurooncol       Date:  2015-06-21       Impact factor: 4.130

8.  Treatment of leptomeningeal spread of NSCLC: a continuing challenge.

Authors:  Seema Nagpal; Jonathan Riess; Heather Wakelee
Journal:  Curr Treat Options Oncol       Date:  2012-12

9.  Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report.

Authors:  Jennie W Taylor; Eoin P Flanagan; Brian P O'Neill; Tali Siegal; Antonio Omuro; Lisa Deangelis; Joachim Baehring; Ryo Nishikawa; Fernando Pinto; Marc Chamberlain; Khe Hoang-Xuan; Alberto Gonzalez-Aguilar; Tracy Batchelor; Jean-Yves Blay; Agnieszka Korfel; Rebecca A Betensky; Maria-Beatriz S Lopes; David Schiff
Journal:  Neurology       Date:  2013-10-09       Impact factor: 9.910

10.  Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Authors:  Xuling Lin; Martin Fleisher; Marc Rosenblum; Oscar Lin; Adrienne Boire; Samuel Briggs; Yevgeniya Bensman; Brenda Hurtado; Larisa Shagabayeva; Lisa M DeAngelis; Katherine S Panageas; Antonio Omuro; Elena I Pentsova
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.